A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2020
CompletedFirst Posted
Study publicly available on registry
April 7, 2020
CompletedMay 5, 2021
May 1, 2021
April 3, 2020
May 3, 2021
Conditions
Interventions
Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Eligibility Criteria
You may qualify if:
- Biochemical Recurrent Prostate Cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prostate Oncology Specialists
Marina del Rey, California, 90292, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2020
First Posted
April 7, 2020
Last Updated
May 5, 2021
Record last verified: 2021-05